| Objective". To investigate the correlation of PPARγ2 gene Prol2Ala polymorphism with type 2 diabetes mellitus and its macroangiopathy in Chinese .Methods : According to WHO 1999 criteria, 198 type 2 diabetic inpatientswere selected (male 105 cases, female 93 cases, average age 59.33±10.92) from the medical ward of Endocrine during April to November of 2006. They were divided into two groups: group A were 124 cases without macroangiopathy (male 65 cases, female 59 cases, average age 55.72±11.66) ; group B were 74 cases with macroangiopathy (male 40 cases, female 34 cases, average age 64.77±8.41 ) .The control group was composed of healthy check-up outpatients (male 55 cases, female 43 cases, average age 58.89±10.18, without Diabetes Mellitus, hypertension, family history of Diabetes Mellitus or hypertension). The genotypes of Pro12Ala variant in PPARγ2 gene were determined by polymerase chain reaction-restriction fragment length polymorphisms (PCR-RFLP) assay. The frequencies of PPARγ2 Pro12Ala genotype and allele gene were compared among them. In each group, body mass index (BMI), waist, systolic blood pressure(SBP). diastolic blood pressure(DBP). fasting blood glucose (FPG), fasting insulin (FINS), Homeostasis model assessment of insulin resistance (HOMA-IR), glycosylated hemoglobin(HbA1c), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and lipoprotein a (Lp(a)) were compared between Pro/Pro subgroup and Pro/Ala subgroup.Results:1. The frequencies of Pro/Pro, Pro/Ala and Ala/Ala genotype of PPARy2 gene are 0.914 0.082 and 0.004 respectively; The frequencies of Pro allele and Ala allele are 0.955 and 0.045. The frequencies of genotype~▲and allele~* are not significantly different between people in diabetes and control group (P~▲= 0.379; P~* = 0.670). The frequencies of genotype~▲and allele~* are also not significantly different between people in group A and B (P~▲= 0.804; P~* = 0.637).2. The number of SBP, DBP, FPG, HOMA-RI Fib in diabetic group are significantly higher than those in the control group(P <0.05), while HDL-C is lower(P <0.05).3. Compared with type 2 diabetes patients without macroangiopathy, the diabetic patients with macroangiopathy have much higher levels of ages (64.77±8.41 vs 55.72±11.66), SBP(148.84±21.89 vs 138.24±20.43), Fib(3.78±1.01 vs 3.32±0.89) duration of diabetes (11.68±6.11 vs 7.91±5.98). duration of hypertension (8.39±10.06 vs 3.3±7.23), and lower HDL-C (1.15±0.26 vsl.67±0.85) (P <0.01).4. In diabetic group, there is no association between PPARy2 gene Pro12Ala polymorphism and clinical characteristics, such as BMI, SBP, DBP, FPG, FINS, HOMA-IR, HbA1c, TC, TG, HDL-C, LDL-C, Lp(a) and so on.5. In control group, people with Ala allele have lower FPG than those with only Pro allele(P<0.05). Stepwise regression analysis shows that PPARγ2-Pro12Ala, FINS are independent risk factors for FPG.6. In group A , there is no association between PPARγ2 gene Pro12Ala polymorphism and clinical characteristics, such as BMI, SBP, DBP, FPG, FINS HOMA-IR, HbA1c, TC TG, HDL-C, LDL-C. Lp(a) and so on.7. In group B, people with Ala allele have higher WHR than those only with Pro allele(P <0.05).Stepwise regression analysis shows that waist BMI PPARγ2-Pro12Ala are independent risk factors for WHR.8. Logistic regression shows that HOMA-RI FINS and SBP are the major risk factors for diabetes and the major risk factors for macroangiopathy are ages, duration of hypertension and Lp(a).Conclusion: PPARy2 gene Pro12Ala polymorphism is not associated withthe incidence of T2DM and its macroangiopathy in Chinese. But people with Ala allele have lower FPG in control group and higher WHR in group B than those with only Pro allele. Logistic regression shows that HOMA-RL FINS and SBP are the major risk factors for diabetes and the major risk factors for macroangiopathy are ages, the duration of hypertension and Lp(a). |
PDF Full Text Request